XML 61 R51.htm IDEA: XBRL DOCUMENT v3.21.2
ACQUISITIONS - Narrative (Details)
€ in Millions
3 Months Ended 9 Months Ended
Mar. 04, 2021
USD ($)
Mar. 04, 2021
EUR (€)
Oct. 23, 2020
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Mar. 31, 2021
USD ($)
Mar. 04, 2021
EUR (€)
Business Combination, Separately Recognized Transactions [Line Items]                      
Acquired in-process research and development expenses       $ 19,000,000   $ 1,171,000,000   $ 177,000,000 $ 5,792,000,000    
Forty Seven, Inc.                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Consideration, net of acquired cash             $ 4,700,000,000        
Acquired share-based compensation expense                 144,000,000    
Acquired IPR&D | Forty Seven, Inc.                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Acquired in-process research and development expenses                 $ 4,500,000,000    
MYR GmbH                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Acquisition consideration transferred $ 1,600,000,000 € 1,300                  
Cash paid for acquisition 1,200,000,000 € 1,000                  
Fair value of contingent liability 341,000,000                    
Finite-lived intangible assets 845,000,000                    
Goodwill 226,000,000                    
Expected tax deductible goodwill       0       0      
MYR GmbH | Level 3 | Fair Value, Measurements, Recurring                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Liability for MYR GmbH (“MYR”) contingent consideration       $ 328,000,000 $ 0     $ 328,000,000   $ 341,000,000  
MYR GmbH | Maximum                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Liability for MYR GmbH (“MYR”) contingent consideration | €                     € 300
MYR GmbH | Hepcludex For HDV                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Finite-lived intangible assets $ 845,000,000                    
Weighted average useful life 10 years 10 years                  
MYR GmbH | Hepcludex For HDV | Discount Rate                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Measurement input 0.12                   0.12
MYR GmbH | Acquired IPR&D | Discount Rate                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Measurement input 0.12                   0.12
Immunomedics                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Acquisition consideration transferred     $ 20,600,000,000                
Goodwill     $ 3,991,000,000                
Immunomedics | Three-Year Senior Term Loan Facility | Medium-term Notes                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Borrowing from senior unsecured term loan facility         $ 1,000,000,000